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After more than 50 years of research, airway transplantation remains a major challenge in the fields of thoracic
surgery and regenerative medicine. Five principal types of tracheobronchial substitutes, including synthetic
prostheses, bioprostheses, allografts, autografts and bioengineered conduits have been evaluated experimentally in
numerous studies. However, none of these works have provided a standardized technique for the replacement of
the airways. More recently, few clinical attempts have offered encouraging results with ex vivo or stem cell–based
engineered airways and tracheal allografts implanted after heterotopic revascularization. In 1997, we proposed a
novel approach: the use of aortic grafts as a biological matrix for extensive airway reconstruction. In vivo
regeneration of epithelium and cartilage were demonstrated in animal models. This led to the first human
applications using cryopreserved aortic allografts that present key advantages because they are available in tissue
banks and do not require immunosuppressive therapy. Favorable results obtained in pioneering cases have to be
confirmed in larger series of patients with extensive tracheobronchial diseases.
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Tracheal surgeryReview
Inhibition to tracheal surgery before 1960 was explained
by difficulties related to perioperative ventilation, the poor
healing capacity of cartilage and, finally, the “2-cm Belsey
rule” stipulating that it was not possible to remove more
than 2 cm of the trachea with primary reconstruction [1].
With the experimental and clinical studies stimulated over
the past 50 years by Hermes C Grillo of Boston and some
other surgeons around the world, all problems have been
solved to provide a standardized approach to tracheal sur-
gery [2]. In summary, using mobilization procedures,
current surgical techniques permit the resection of ap-
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reproduction in any medium, provided the orby primary anastomosis [3]. Proven methods are also
available for laryngotracheal as well as carinal resection
and reconstruction [4,5]. All problems have been solved,
except one: the surgical treatment of extensive lesions
where tracheal resection with primary anastomosis is not
possible or is associated with a high rate of morbidity and
mortality. As a result, patients with these lesions are only
offered palliative care. To envision tracheal reconstruction
after resection of extended lesions, we are in need of a tra-
cheal substitute. Significant advances in medicine have
allowed the successful replacement of complex organs. In
contrast, attempts to replace the trachea, a rather simple
conduit dedicated to the passage of air, have failed [6].
Thus, tracheal replacement remains today a great surgical
and biological challenge.Airway transplantation: the five main methods of
research
In 2004, the various tracheal substitutes and techniques
of reconstruction were classified by Grillo into five cat-
egories: foreign materials, nonviable tissues, trachealal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gineering [6]. The ideal airway substitute has to be a
biocompatible rigid but flexible tube that should facili-
tate reepithelialization, integrate with adjacent tissues
and be resistant to stenosis and bacterial colonization.
Attempts to do this with the use of foreign materials led
to chronic infection, airway obstruction, migration of
the prosthesis, erosion into major blood vessels and
proliferation of granulation tissue. Implantation of
nonviable tissues–chemically treated, frozen or lyophi-
lized–has been associated with poor functional results.
Tracheal allotransplantation has also been disappoint-
ing because of complications of graft necrosis or sten-
osis. In addition, immunosuppressive therapy should not
be prescribed for the treatment of a malignancy. Conse-
quently, these approaches have increasingly been aban-
doned. Reconstructions with autogenous tissues such as
skin, fascia lata, pericardium, costal cartilage, bladder,
esophagus or bowel are complex procedures. They have
led to unsatisfactory results, with the possible exception of
muscle or cartilage flaps. Since the pioneering studies by
Vacanti and colleagues [7,8], efforts have been made to in-
duce the formation of cartilaginous tubes covered with
epithelial cells using tissue-engineering techniques. At the
time Grillo wrote his reference textbook, tracheal replace-
ment using the tissue-engineered technique had not yet
been applied to malignant tumors, as it required the use
of the patient’s own cells and because several months were
required to construct the graft. Reviews on airway trans-
plantation have usually concluded that none of the
proposed tracheal substitutes offer consistent results suffi-
cient to consider a standardized approach [6,9,10].
Development of ex vivo tissue engineering
Since the publication of Grillo’s textbook, significant ad-
vances have been observed in the area of ex vivo tissue
engineering based on the use of stem cells [11,12]. The
modern area of stem cell research started effectively in
the mid-20th century and permitted the definition of
fundamental properties of stem cells, such as self-
renewal, clonogenicity and multipotentiality. These de-
velopments have allowed identification and classification
of stem cells from totipotent to pluripotent, multipotent
and progenitor cells. They also have led to culture and
differentiation of stem cells to consider their use in ther-
apy and tissue engineering. The use of embryonic or
tissue-specific adult stem cells has recently been pro-
posed for the treatment of various human disorders. In
addition, ex vivo tissue engineering has emerged as a
possible solution for tissue reconstruction. This method
requires cultivated human cells, which are seeded in
scaffolds using artificial bioreactors before implantation
of the engineered structures. In 2008, the team directed
by Birchall in London reported the first case of tissue-engineered airway transplantation in a patient with post-
tuberculosis end-stage bronchomalacia [13]. Recipient
epithelial cells and mesenchymal stem cell–derived
chondrocytes were cultivated and seeded onto a
decellularized human donor trachea within an artificial
bioreactor. The authors reported that favorable results
were seen 4 months after implantation. This technique
has some limitations, however because of the shortage of
human tracheal donors. Furthermore, it cannot be used in
cancer lesions, because the patient’s epithelial cells are
needed and a few months are necessary to obtain the graft.
In 2011, some members of Birchall’s initial group reported
the use of a bioartificial nanocomposite instead of a
decellularized human donor trachea [14]. The bioartificial
nanocomposite was seeded with autologous bone marrow
mononuclear cells onto an artificial bioreactor. This tech-
nique was performed in a first patient with recurrent ex-
tensive cancer. The authors observed stem cell homing
and cell-mediated wound repair with extracellular matrix
remodeling and neovascularization of the graft. Stem
cell mobilization and apoptosis inhibition were due to
boosting and growth factor administration [15]. The re-
sults were positive after 5 months of follow-up. In 2012,
Elliott and colleagues reported the case of the first
pediatric patient who had stem cell–based, tissue-
engineered tracheal replacement, with encouraging results
after 2 years of follow-up [16]. In 2010, Delaere and col-
leagues in Leuven reported a new surgical procedure
performed in one patient with extensive post-traumatic
stenosis [17]. While the patient was receiving immunosup-
pressive therapy, a tracheal allograft was wrapped in the
recipient’s forearm fascia. The tracheal allograft was pro-
gressively revascularized and fully lined with donor re-
spiratory epithelium and recipient buccal mucosa. After
withdrawal of immunosuppressive therapy at 4 months,
the tracheal allograft was moved to its anatomical position
with an intact blood supply. Satisfactory results were
obtained with a 1-year follow-up. In addition to the need
for immunosuppressive therapy, problems related to this
treatment modality are similar to those observed with
ex vivo engineered airways.
Use of aortic matrix for airway transplantation
The complex approach of ex vivo tissue engineering has
been unable to recreate functional regenerated tissues or
organs in most attempts. Thus, some investigators have
proposed the use of the human body as a natural bio-
reactor to achieve in vivo tissue engineering [18]. In
1997, we proposed a different approach to airway trans-
plantation. During our preliminary work on tracheal re-
placement, we noticed that one structure had been
ignored: the aorta. This biological structure has major
advantages; it is a tubular conduit with a diameter simi-
lar to the trachea’s. Moreover, it is well-known for its
Figure 2 Histologic examination of cryopreserved aortic
allograft at 2 months (sheep model) showing regenerated
cartilage (hematoxylin and eosin staining; original
magnification ×10).
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other hand, it has a major disadvantage: the risk of col-
lapse. However, this can be avoided by the use of a stent.
Our work has been performed in successive steps using
as tracheal substitutes aortic autografts, then fresh and
cryopreserved allografts [19-25]. No complications oc-
curred in the majority of animals during a maximum
follow-up of 3 years. The macroscopic evaluation was
very surprising. First, there was no stenosis in cases
where a stent was inserted into the graft. Second, there
was an unexpected tracheal regeneration, including epi-
thelium and cartilage (Figures 1 and 2). This regenera-
tive process was also observed after replacement of the
carina. At the beginning of our experiments, we used a
nitinol stent. Facing the regeneration of cartilage, we de-
cided to remove the stent. It was impossible, however,
because of major adhesions following the use of this type
of stent. As a result, we placed a silicone stent into the
graft. Removal was easy, and there were no clinical con-
sequences. This showed that the regenerated cartilage
was functional. Histological examinations showed a pro-
gressive regeneration of epithelium from an inflam-
matory tissue to a squamous, mixed and mucociliary
epithelium. The phenomenon we observed was similar
to that seen in the repair described by others after epi-
thelium destruction. This is a well-documented process
arising from basal and mucosal cells of the native tra-
chea. At all intervals, we found residual elastic fibers
from the aortic tissue. The inflammatory process was as-
sociated with reconstruction by fibroblasts secreting col-
lagen. To discover whether cartilage came from aortic
cells or from recipient cells, we decided in the six last
animals in the allograft study to implant aorta from male
sheep to trachea of female sheep and to search for SRYFigure 1 Histologic examination of cryopreserved aortic
allograft at 6 months (sheep model) showing regenerated
airway epithelium (hematoxylin and eosin staining; original
magnification ×2.5).genes in the newly formed cartilage. Using a type 2 col-
lagen marker, we demonstrated that newly formed struc-
tures within the aortic graft were indeed cartilage. PCR
studies showed SRY amplification for male specimens
but no amplification for female specimens or the newly
formed cartilage. This clearly showed that newly formed
cartilage originated not from aortic cells but from recipi-
ent cells. Today we know that this process did not come
from aortic cells. Furthermore, chondrocytes cannot mi-
grate, and newly formed cartilage was distant from the
native trachea. These two points evidently refute the possi-
bility of regeneration from the native cartilage. The last
hypothesis is that regeneration came from mesenchymal
cells, local cells or, most probably, circulating stem cells
from bone marrow, as this has been demonstrated for the
repair of other organs. This was recently confirmed by
our group in a rabbit model [26]. Cryopreserved aortic
allograft seems to be the better option in the view of hu-
man applications because of availability in tissue banks,
permanent storage and no need for immunosuppres-
sion. We demonstrated that regeneration of a functional
tissue could also be obtained after tracheal replacement
with cryopreserved aortic allografts, in contrast to
decellularized or glutaraldehyde-treated aortic grafts
[25]. The regenerative process followed the same pat-
tern as previously described for fresh allografts. These
results were confirmed in a pig model as discussed by
others [27-29]. We also demonstrated that an arterial
allograft could be a valuable bronchial substitute with
results similar to those obtained after tracheal replace-
ment [30]. We theorized that airway healing after replace-
ment with biological scaffolds was the consequence of a
mixed phenomenon associating airway approximation and
regeneration [31].
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In 2005, a multicentric clinical program started in France
to evaluate this new technique for extensive primary tra-
cheal tumors. Aortic autograft was not used because of
the risk. Fresh, then cryopreserved aortic grafts were eval-
uated in six patients with, in the majority of cases, adenoid
cystic carcinoma [32,33]. Tracheal resection was extended
to the carina in four patients, to the right upper lobe in
one patient and to the left lung in one patient. Carinal re-
construction was performed in three patients. A silicone
stent–supported aortic graft, fresh in two patients or
cryopreserved in four, was used as a tracheal substitute. A
pectoral muscle flap was created. No immunosuppressive
therapy was given. Resection was complete in all patients
but one. There was no postoperative mortality. However,
postoperative morbidity was high, especially in the first pa-
tients. This was mainly due to problems with anastomosis
and the stent or to infection. In long-term evaluation with
a mean follow-up of 34 months, patient 1 died from
metastatic disease at 45 months, patient 2 died from
hemoptysis at 26 months, and the other four patients were
alive and disease-free, three of whom had a full-time occu-
pation. As observed in the experimental phase, the aortic
graft was covered by continuous epithelium. However,
only calcifications were observed. There was no identified
regeneration of mature cartilage. A contraction of the aor-
tic graft was also observed, as previously found in animal
studies [31]. Asymptomatic fistulae between the graft and
esophagus were seen in half of the patients. For all these
reasons, a definitive removal of the stent was not pro-
posed. Our experimental works led also to the first bron-
chial transplantation performed to avoid the high-risk
procedure of pneumonectomy [34]. This operation was
performed in a patient with large proximal lung cancer
and with three factors predictive of postoperative mortal-
ity: age, right side and neoadjuvant chemotherapy. The
first step consisted of complete resection of the lung can-
cer using intrapericardial upper bilobectomy with lymph
node removal. Bronchial resection was performed from
the first centimeter of the right main bronchus to the ori-
gin of the lower lobe bronchus because of extraluminal
adhesions. After opening the pericardium, mobilization
procedures were still limited by the stretching of the infer-
ior pulmonary vein and kinking of the pulmonary artery.
Reconstruction was performed using a cryopreserved aor-
tic allograft from a certified tissue bank. A custom-made,
fully covered, conical nitinol stent (Silmet; Novatech, La
Ciotat, France) was inserted into the graft to prevent air-
way collapse. This stent was specially fabricated for this in-
novative procedure and for this patient. At the end of the
operation, the sparing right lower lobe reexpanded nor-
mally, and there was no anastomotic leakage. No im-
munosuppressive therapy was given. In the postoperative
course, we observed a supraventricular arrhythmia leadingto mild pulmonary edema that resolved after 24 hours of
standard medical therapy and right lower lobe atelectasis
with bronchial colonization that required fiberoptic bron-
choscopies in addition to antibiotic treatment. Chest tubes
were removed at day 5, and the patient was discharged at
day 16 with a normal CT scan showing a functional right
lower lobe. Pathologic examinations confirmed radical
surgical resection. After follow-up of 1 year, we con-
cluded that the operation was feasible with no technical
problems, that there was no major complication associ-
ated with this procedure during the postoperative
period, that the reimplanted right lower lobe remained
functional with no complications related to the stent or
the cryopreserved aortic allograft, that pulmonary func-
tion after the operation remained largely superior to the
third of the predicted value and, finally, that the health-
related quality of life of the patient was preserved. A
prospective phase 1 feasibility study is now in progress
at our center (TRACHEOBRONCART Trial).
Conclusions
It is still unclear whether we are closer to the Holy Grail
of airway transplantation with the use of cryopreserved
aortic allografts. However, what we know is that this
structure could have key advantages because it is a bio-
logic structure available at tissue banks. In addition, this
ideal matrix promoted in vivo in situ tissue engineering
in animal models. Moreover, this matrix can be used for
benign and cancerous lesions. The current difficulties
are related to the delayed cartilage regeneration and the
need for a permanent stent in human. This requires new
studies to establish a standardized solution to the thus
far unsolved problem of airway transplantation.
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